Do you want to read an article? Please log in or register.
Vedolizumab in early and late Crohn's disease (LOVE-CD): a phase 4 open-label cohort study
Inflammatory Bowel Disease
Related content
Inflammatory Bowel Disease
Efficacy and Safety of Risankizumab in Patients with Moderately to Severely Active Crohn's Disease: Interim Results from the SEQUENCE Open-Label Extension Study
J Crohns Colitis
Peyrin-Biroulet L, Atreya R, Danese S, Lindsay JO, Chapman JC, Anschutz T, Huang X, Zambrano J, van Haaren S, Joshi N, Duan WR, Cross RK
doi: 10.1093/ecco-jcc/jjaf213
Inflammatory Bowel Disease
Deucravacitinib in Patients With Inflammatory Bowel Disease: 12-Week Efficacy and Safety Results From Three Randomized Phase 2 Studies in Crohn's Disease and Ulcerative Colitis
J Crohns Colitis
D'Haens G, Danese S, Panaccione R, Rubin DT, Peyrin-Biroulet L, Matsuoka K, Loftus EV Jr, Kobayashi T, Elsharkawi W, Miceli R, Ahmed S, Luo Y, Napoli A, Vaile J, Dornic Q, Patel A, Schreiber S
doi: 10.1093/ecco-jcc/jjaf080
Inflammatory Bowel Disease
Subcutaneous Infliximab (CT-P13 SC) as Maintenance Therapy for Crohn's Disease and Ulcerative Colitis: 2-Year Results from Open-Label Extensions of Two Randomized Controlled Trials (LIBERTY)
J Crohns Colitis
Colombel JF, Sandborn WJ, Schreiber S, Danese S, Kłopocka M, Kierkuś J, Kulynych R, Gonciarz M, Sołtysiak A, Smoliński P, Srećković S, Valuyskikh E, Lahat A, Horyński M, Gasbarrini A, Osipenko M, Borzan V, Kowalski M, Saenko D, Sardinov R, Lee SJ, Kim S, Bae Y, Lee S, Lee S, Lee JH, Kim JM, Park G, Lee J, Lee J, Ryu JY, Sands BE, Hanauer SB
doi: 10.1093/ecco-jcc/jjaf060
COMMENTED
Inflammatory Bowel Disease
Intestinal Ultrasound Findings and Their Prognostic Value in Early Crohn's Disease - a Copenhagen IBD Cohort Study
★ 1
Recommended and commented by
Prof. Dr Stephan Vavricka, Faculty Member
Clin Gastroenterol Hepatol
Madsen GR, Attauabi M, Ilvemark JFKF, Theede K, Bjerrum JT, Bendtsen F, Seidelin JB, Wilkens R, Boysen T, Burisch J
doi: 10.1016/j.cgh.2024.12.030
Inflammatory Bowel Disease
Long-term safety of vedolizumab in patients with ulcerative colitis/Crohn's disease: A prospective observational study
Clin Gastroenterol Hepatol
Louis E, Sebastian S, Siegmund B, Bossuyt P, Danese S, de Boer N, Loftus EV, Moum B, Peyrin-Biroulet L, Schreiber S, Zhou J, Angellotti E, Adsul S, Jones S, Siegel CA
doi: 10.1016/j.cgh.2025.10.006
Further Publications
Early tumour necrosis factor antagonist treatment prevents perianal fistula development in children with Crohn's disease: post hoc analysis of the RISK study
Gut
Adler J, Gadepalli S, Rahman M, Kim S
doi: 10.1136/gutjnl-2024-333280
Inflammatory Bowel Disease
Upadacitinib Maintenance Therapy in Crohn's Disease: Final Results From the Randomized Phase 3 U-ENDURE Study
Clin Gastroenterol Hepatol
Panaccione R, Regueiro M, Lee SD, Atreya R, Pedersen G, Broide E, Rodriguez C, van Bodegraven AA, Dubcenco E, Lacerda AP, Feng T, Geng Z, Wang T, van Haaren S, Anyanwu SI, Panés J
doi: 10.1016/j.cgh.2025.07.028
Inflammatory Bowel Disease
Mirikizumab Improves Quality of Life and Work Productivity in Patients with Moderately to Severely Active Crohn's Disease: Results from the Phase 3 VIVID-1 study
Am J Gastroenterol
Lee SD, Vermeire S, Ungaro R, Vadhariya A, Durand F, Morris N, Yu G, Fisher DA, Traxler K, Long M
doi: 10.14309/ajg.0000000000003410
Inflammatory Bowel Disease
Efficacy and Safety of Guselkumab Subcutaneous Induction and Maintenance in Participants with Moderately to Severely Active Crohn's Disease: Results from the Phase 3 GRAVITI Study
Gastroenterology
Hart A, Panaccione R, Steinwurz F, Danese S, Hisamatsu T, Cao Q, Ritter T, Seidler U, Olurinde M, Vetter ML, Yee J, Yang Z, Wang Y, Johanns J, Han C, Sahoo A, Terry NA, Sands BE, D'Haens G
doi: 10.1053/j.gastro.2025.02.033